Evidence map›Paper›PMID 41186833›Full record

ArticleJournal of hematopathology2025

Staging FDG PET/CT prediction of bone marrow involvement by diffuse large B-cell lymphoma leading to delayed recognition of multiple myeloma.

Amanda C Gibbs, Prem P Batchala, Chelsea E Gottlieb, Bryan O Balle, Ifeyinwa E Obiorah, Laahn H Foster, Emily C Ayers, Jeffrey W Craig

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hematopathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Dynamic changes in serum IL-6, TNF-Frontiers in medicine · 2026
    Article
  3. Karyotype evolution of multiple myeloma.Journal of clinical and experimental hematopathology : JCEH · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Amanda C GibbsDepartment of Pathology, University of Virginia Health System (UVA Health), 1215 Lee Street, PO Box 800904, Charlottesville, VA, 22908-0904, USA.
Prem P BatchalaDepartment of Radiology and Medical Imaging, UVA Health, Charlottesville, VA, USA.
Chelsea E GottliebCharlottesville Pathology Associates, Charlottesville, VA, USA.
Bryan O BalleDepartment of Pathology, University of Virginia Health System (UVA Health), 1215 Lee Street, PO Box 800904, Charlottesville, VA, 22908-0904, USA.
Ifeyinwa E ObiorahDepartment of Pathology, University of Virginia Health System (UVA Health), 1215 Lee Street, PO Box 800904, Charlottesville, VA, 22908-0904, USA.
Laahn H FosterDepartment of Medicine - Hematology/Oncology, UVA Health, Charlottesville, VA, USA.
Emily C AyersDepartment of Medicine - Hematology/Oncology, UVA Health, Charlottesville, VA, USA.
Jeffrey W CraigDepartment of Pathology, University of Virginia Health System (UVA Health), 1215 Lee Street, PO Box 800904, Charlottesville, VA, 22908-0904, USA. jwc3q@uvahealth.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background18-Fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) scans have largely replaced bone marrow biopsy in the staging workup for diffuse large B-cell lymphoma (DLBCL). PURPOSE/

methodsHere, we highlight a pitfall of FDG PET/CT for assessing bone marrow involvement, detailing the clinical course of a patient diagnosed with otherwise limited-stage DLBCL who exhibited diffuse bone marrow FDG uptake, felt to be compatible with extensive lymphomatous infiltration. In accordance with current National Comprehensive Cancer Network guidelines, this finding circumvented the need for a formal staging bone marrow biopsy procedure.

resultsSubsequent clinical developments revealed extensive bone marrow involvement by a second, unexpected malignancy (multiple myeloma), casting doubt on the assumption that the initial diffuse marrow uptake was attributable to DLBCL.

conclusionThe presented case emphasizes the challenges of interpreting diffuse FDG uptake within the bone marrow compartment and highlights the inherent contribution of histomorphology for the accurate diagnosis and classification of hematolymphoid neoplasms.

Indexed as

Bone MarrowFluorodeoxyglucose F18Lymphoma, Large B-Cell, DiffuseMultiple MyelomaPositron Emission Tomography Computed TomographyAgedFemaleHumansNeoplasm StagingRadiopharmaceuticalsFluorodeoxyglucose F18RadiopharmaceuticalsBone marrowDiffuse large B-cell lymphomaPlasma cell myeloma/multiple myelomaPositron emission tomography/computed tomographyStaging

Identifiers

PMID41186833
PMCPMC12586389

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.